Core Viewpoint - The announcement details a significant partnership and investment involving昊海生物科技,亨泰光学, and亨泰视觉, which includes exclusive distribution rights and equity acquisition, indicating a strategic move to enhance market presence in the optical lens sector [1][2]. Group 1: Exclusive Distribution Agreement -昊海生物科技's subsidiary,昊海控股, has signed an exclusive distribution agreement with亨泰光学 and亨泰视觉 for high-end orthokeratology contact lenses "迈儿康myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also grants昊海控股 exclusive distribution rights for children's myopia management optical lenses "贝视得" in mainland China [1]. Group 2: Equity Acquisition -昊海发展, another subsidiary of昊海生物科技, has entered into an investment agreement to acquire a 55% stake in亨泰视觉 for RMB 25 million, making亨泰视觉 a controlled subsidiary and included in the consolidated financial statements of the company [1]. - Following a change in control of亨泰光学 due to a proposed acquisition by Carl Zeiss Vision International GmbH,昊海控股 and亨泰光学's major shareholders have signed a termination agreement for the existing cooperation [2]. - As part of the termination agreement,亨泰光学's major shareholders will pay昊海控股 a termination compensation of RMB 80 million [2].
昊海生物科技与亨泰光学终止OK镜独家合作 获8000万元补偿并全资控股亨泰视觉